Ironwood Pharmaceuticals reports positive phase IIB GERD therapy data — 4 insights

Ironwood Pharmaceuticals reported results from its phase IIB trial for IW-3718, its gastroesophageal reflux disease therapy.

Researchers combined IW-3718 with a proton pump inhibitor. The combination therapy significantly reduced heartburn severity in uncontrolled GERD patients.

Here's what you should know:

1. Researchers analyzed data from 282 patients. The patients took a twice-daily oral dose of the therapy.

2. More than half of the patients achieved a "clinically meaningful reduction" in heartburn severity.

3. The therapy was well tolerated.

4. Ironwood will meet with the FDA to discuss the trial before advancing to phase III development in the latter half of 2018.

More articles on gastroenterology:
GI center to know: Eugene Gastroenterology Consultants
CMS proposes 2018 endoscopy anesthesia updates: 5 key highlights from CRH Anesthesia
GI leader to know: Dr. Alexandria Phan of Cancer Treatment Centers of America

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast